Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

ZD-4522 enters accelerated phase III trial program

Feb. 16, 1999

Cellegy initiates clinical trial with transdermal testosterone gel

Feb. 15, 1999

Neurogen and Pfizer collaborate on development of NPY receptor ligands

Feb. 12, 1999

Genentech to withdraw support from pimagedine development

Feb. 11, 1999

Urologix's Targis System superior to alpha-blockers in BPH therapy

Feb. 11, 1999

Cathepsin L inhibitor isolated by Yamanouchi

Feb. 10, 1999

G120K-PEG: a specific renal GHR antagonist for the treatment of diabetic kidney disease

Feb. 10, 1999

Cholesterol-lowering action of troglitazone points to a potential new target for hypolipidemic drugs

Feb. 10, 1999

NIH to initiate clinical trials of Novavax's Novasome spermicide

Feb. 10, 1999

Metabolism of potent new progestagen examined in vitro and in vivo

Feb. 9, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.